Viega Breaks Ground for New Headquarters in Broomfield

Leading supplier in construction and plumbing industry to build corporate headquarters and training facility at new Denver-area campus.

BROOMFIELD, Colo., June 26, 2017 /PRNewswire/ — Viega LLC broke ground on Tuesday, June 20 for its new corporate headquarters and new training facility off of Interlocken Boulevard.

The groundbreaking was attended by local Viega colleagues and family members, Viega Group representatives from the global headquarters in Attendorn, Germany and local Broomfield officials

Situated on 11.8 acres, Viega LLC’s Broomfield campus will be home to a state-of-the-art, 55,000-square-foot North American headquarters as well as a 24,000-square-foot training facility. The new headquarters will be a Class A office building featuring a sweeping curved roof, a design inspired by Viega’s innovative fittings. The building will incorporate a variety of Viega solutions including press fittings, fire suppression systems, radiant heating and cooling, carrier systems and manifolds. A courtyard will feature Viega’s radiant snow melt systems.

The new training facility is in addition to the company’s existing training facility located in Nashua, N.H. and will expand Viega’s training capacity. The facility will offer hands-on, interactive training on Viega systems and solutions. The training facility will also incorporate and highlight Viega fittings, radiant heating and cooling systems, fire suppression systems and carrier systems.

Glass curtain walls in both buildings will let in natural light as well as showcase great views. Estimated completion for both buildings is late 2018.

“We’ve received such a warm welcome in Colorado already and are excited to establish our new campus. Our new state-of-the-art headquarters and training center will provide a working environment that our colleagues and customers deserve and will highlight our innovative products,” said David Garlow, CEO, Viega LLC. “The growth in this area shows no signs of slowing and there is a wealth of talent here that has already strengthened our team.”

Land use has been optimized to position the company for future growth and development at the site. Close proximity to the Denver International Airport will also make Viega more accessible to customers and partners.

Viega LLC employs nearly 600 people in North America, with a central manufacturing and distribution center in McPherson, Kansas, as well as distribution centers in Nevada, Georgia and Pennsylvania, and a training facility in New Hampshire.

About Viega:
The Viega Group, with a tradition of innovation for more than 115 years, has more than 4,000 employees worldwide and is among the leading manufacturers of pipe fitting installation technology. In metal press systems for industrial, commercial and residential projects, the company is the global market leader. In the U.S., Viega LLC employs nearly 500 people and offers more than 3,000 products. These include Viega ProPress® for copper and stainless, Viega MegaPress® for black iron pipe and Viega PEX Press systems in Zero Lead™ bronze and high-performance polymer. Viega also specializes in the design, production and installation of ProRadiant™ heating and cooling systems. For more information, visit


Kitov Updates on KIT-302 New Drug Application

Anticipated PDUFA Date with FDA for Approval of Marketing on Schedule

TEL AVIV, Israel, June 26, 2017 /PRNewswire/ —

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that it has begun the process of digitizing its New Drug Application (NDA) for KIT-302, its lead drug candidate, through Parexel International Corporation, a clinical research organization, which has been engaged by Kitov for the preparation of the NDA into the standard, accepted electronic format of the U.S. Food and Drug Administration (FDA). KIT-302 is Kitov’s patented combination of celecoxib and amlodipine, is intended to treat osteoarthritis pain and hypertension simultaneously.

In accordance with the FDA’s usual practice, within 60 days of its receipt of the electronic submission of the complete set of NDA modules, the FDA is expected to determine whether the NDA is complete and acceptable for filing. As such, Kitov expects that the formal filing of the NDA by the FDA will occur by the end of the third quarter of 2017.

“While we experienced unexpected delays in the provision of certain technical documentation from external service providers, we are pleased with the quality of our NDA submission modules, and we expect the FDA to complete its review and filing of the NDA within the standard 60 days” stated J. Paul Waymack, M.D., Sc.D., Kitov’s Chairman of the Board and Chief Medical Officer. Dr. Waymack added, “We are still on track to meet our anticipated Prescription Drug User Fee Act (PDUFA) date with FDA approval for marketing of KIT-302, during the second quarter of 2018. The data in KIT-302’s pivotal Phase III clinical trial were generated, collected, validated and analyzed by leading independent clinical research organizations and service providers, and demonstrated that the Phase III study of KIT-302 met its primary endpoint with statistical significance of 0.001. Given the excellent results of our Phase III clinical trial we are confident that KIT-302 will be approved by the FDA and become a successful treatment for osteoarthritis and hypertension.”

About Kitov Pharmaceuticals  

Kitov Pharmaceuticals (NASDAQ: KTOV, TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, KIT-302, intended to treat osteoarthritis pain and hypertension simultaneously, achieved the primary efficacy endpoint for its Phase III clinical trial. Kitov’s newest drug, NT219, which is developed by its majority owned subsidiary, TyrNovo Ltd., is a small molecule that presents a new concept in cancer therapy, and in combination with various approved oncology drugs, demonstrated potent anti-tumor effects and increased survival in various cancer models. By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives. For more information on Kitov, the content of which is not part of this press release, please visit

Forward-Looking Statements and Kitov’s Safe Harbor Statement  

Certain statements in this press release are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical public disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial and other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and other factors that are discussed in our in our Annual Report on Form 20-F for the year ended December 31, 2016 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website,

Simcha Rock
Chief Financial Officer
+972-3-9333121 ext. #105

Bob Yedid
Managing Director
LifeSci Advisors, LLC

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Arconic Inc. (ARNC; ARNC-P; ARNC-PB)

NEW YORK, June 26, 2017 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arconic Inc. (“Arconic” or the “Company”) (NYSE: ARNC; ARNC-P; ARNC-PB). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:

The investigation concerns whether Arconic and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On June 24, 2017, The New York Times issued a report, “Why Grenfell Tower Burned: Regulators Put Cost Before Safety”, recounting the sources of the June 14, 2017 fire at the Grenfell Tower apartment complex in London, England that killed 79 people.  The article described how Grenfell Tower’s façade consisted of panels containing combustible polyethylene cores, manufactured and promoted by Arconic, that “enabled the fire to spread rapidly on the exterior of the building.”  The article continued to state that Arconic’s U.K. marketing resources for the façade panels contain a less thorough safety warning than Arconic’s marketing materials for other countries.  Following this news, Arconic stock has dropped as much as $2.89, or 11.32%, during intraday trading on June 26, 2017.

If you are aware of any facts relating to this investigation, or purchased Arconic shares, you can assist this investigation by visiting the firm’s site: You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 |

SOURCE Bronstein, Gewirtz & Grossman, LLC

Swing into the World of Spider-Man(TM) with New Exhibit at Sony Square NYC

Check out props from Spider-Man: Homecoming and Experience What it’s Like to Fly Through the Streets of Queens, NY

NEW YORK, June 26, 2017 /PRNewswire/ — Calling all Spider-Man fans!  Whether you are a die-hard fan or a family looking for a free way to entertain your aspiring superheroes, stop by Sony Square NYC and be surrounded by all things Spider-Man. 

In anticipation of the July 7th U.S. theatrical release of Columbia Pictures’ “Spider-Man: Homecoming,” Sony Square NYC is providing an experience worthy of a standing ovation.  Visitors to the showroom will get the chance to step into Peter Parker’s shoes (and leap off a crane to swing through the air in pursuit of Spider-Man’s nemesis The Vulture) in the Spider-Man: Homecoming VR experience on PlayStation®VR.  Visitors will also be able to catch an exclusive viewing experience that creates the feeling of flying through the streets of Queens, New York, just like Spidey.  Plus, props from the film will be on display, including a Spider-Man costume and Peter Parker’s backpack.

Each visitor will also get to leave the exhibit with a keepsake – a photo of themselves flying high above the skyline – just like Spider-Man! 

“‘Spider-Man: Homecoming’ is a movie that will thrill the senses, and it was our goal to give fans the opportunity to experience that excitement before the film opens on July 7,” said Steven Fuld, Senior Vice President, Corporate Marketing, Sony Corporation of America.  “This Spider-Man exhibit is exclusive to Sony Square NYC – it cannot be experienced anywhere else in the world.”

“The Spider-Man: Homecoming” experience is on display from June 26August 6.

Sony Square NYC is located at 25 Madison Avenue and is open to the public Monday through Saturday, from 10 a.m.7 p.m., and Sundays from 11 a.m. – 6 p.m.  For more information, visit

About Spider-Man: Homecoming
In “Spider-Man: Homecoming,” a young Peter Parker/Spider-Man (Tom Holland), who made his sensational debut in Captain America: Civil War, begins to navigate his newfound identity as the web-slinging super hero in “Spider-Man: Homecoming.” Thrilled by his experience with the Avengers, Peter returns home, where he lives with his Aunt May (Marisa Tomei), under the watchful eye of his new mentor Tony Stark (Robert Downey, Jr.). Peter tries to fall back into his normal daily routine – distracted by thoughts of proving himself to be more than just your friendly neighborhood Spider-Man – but when the Vulture (Michael Keaton) emerges as a new villain, everything that Peter holds most important will be threatened.  The movie opens in the U.S. on July 7th.

Directed by Jon Watts. Produced by Kevin Feige and Amy Pascal. Screenplay by Jonathan Goldstein & John Francis Daley and Jon Watts & Christopher Ford and Chris McKenna & Erik Sommers, Screen Story by Jonathan Goldstein & John Francis Daley, Based on the Marvel Comic Book by Stan Lee and Steve Ditko

About Sony Corporation of America
Sony Corporation of America, located in New York, NY, is the U.S. headquarters of Sony Corporation, based in Tokyo, Japan. Sony’s principal U.S. businesses include Sony Electronics Inc., Sony Mobile Communications (USA) Inc., Sony Interactive Entertainment LLC., Sony Pictures Entertainment Inc., Sony Music Entertainment and Sony/ATV Music Publishing LLC. Sony recorded consolidated annual sales of approximately $67.9 billion for the fiscal year ended March 31, 2017 and employs approximately 128,400.


SOURCE Sony Corporation of America

Tessemae’s Expands Clean Label Portfolio With Organic Condiments in More Stores

BALTIMORE, June 26, 2017 /PRNewswire/ — Tessemae’s, a leader in the fresh salad dressing category, is no stranger to condiments. Tessemae’s has been manufacturing condiments in their existing line since 2013.

Tessemae’s has developed a full line of organic condiments to be merchandised in the produce department alongside the current salad dressing line up. The portfolio includes buffalo sauces, mayonnaise, mustards, BBQ sauce and ketchup. The organic Ketchup and organic BBQ sauce are vegan and contain zero added sugars – a differentiator in an otherwise saturated market. These products are championed by diabetics, the paleo community and the Whole30 community. After being introduced on, ketchup and BBQ sauce quickly rocketed to the top to become the #1 and #2 sellers, proving the demand for low sugar or no sugar added condiments in the marketplace.

Tessemae’s will be launching their condiment line in multiple Kroger divisions this month.  Ketchup, BBQ, and Mayo will be available to consumers next to the current dressing line in the refrigerated produce section. Target and Meijer will continue to carry Tessemae’s condiments and the Company has an aggressive roll-out plan with other key retail partners for the balance of the year

Greg Vetter, CEO of Tessemae’s says, “The millennial mom is dictating a majority of the food trend changes today that will continue over the next decade. She wants a clean, delicious tasting option for her family and that ranges from organic produce all the way to fresh condiments. You shouldn’t have to compromise on ketchup for your kids just because ‘it’s always been done this way’. Our condiments change the way you view what’s good for you.”

Tessemae’s continues to field demand for its organic Mayo – one of very few options widely available on shelves that is sugar free. The spread is made with high quality ingredients including cage-free eggs, fresh lemon juice, apple cider vinegar, and sea salt. Organic mayo follows organic ketchup and BBQ as the third best seller on 

“Our Mayo is made just as it should be, using the same real ingredients you’d use to make it at home. Alternate and vegan mayos have been getting a lot of attention lately, and our mayo deserves to share the spotlight. It is the first truly clean label refrigerated mayonnaise: free of gums, sugar and unnecessary preservatives. The result? It’s also the best tasting mayo on the market,” says EVP of R&D for Tessemae’s, Kristen Dittami.

While Tessemae’s is on the fast track for tremendous growth this year, they stand by their original mission: to simplify food and amplify life. They will not be changing formulas or adding ingredients that don’t belong for the sake of cutting costs or pleasing investors.

“The condiment category in the U.S. is now over $6 billion dollars in sales but has not experienced the growth that we think it can because there has been no real innovation. We are here to disrupt that with true, clean label offerings that have a very unique flavor profile which consumers love,” says Vetter.

About Tessemae’s
Tessemae’s is an organic fresh food company that makes products with real, whole ingredients.  The Vetter brothers, Greg, Brian, and Matt, launched the brand in 2009 at their local Whole Foods Market in Annapolis, Maryland, using a simple salad dressing recipe created and used by their mom throughout their childhood.  Tessemae’s commitment to healthy eating and living is the core of their mission. Provide simple, yet delicious food to consumers made with real ingredients.  Available in Whole Foods Market, Kroger, Safeway, Target, The Fresh Market, WalMart, and Earthfare retailers across the country, Tessemae’s products are creating a new standard in the produce department and raising consumer awareness on the importance of consuming real, clean ingredients.  For more information please visit

Contact: Shawn McLaughlin

SOURCE Tessemae’s

New Exposé of Obama Administration’s Arming of Jihadi Terrorists in Syria Is “Wake-Up Call’ for Trump Administration, Says Christian Solidarity International (CSI-USA) Chairman John Eibner

Christian Solidarity International Has Launched No Arms For Terrorists Campaign in Support of the Principles and Purposes of Bi-Partisan H.R. 608/S. 532 “Stop Arming Terrorists Act”

WASHINGTON, June 26, 2017 /PRNewswire-USNewswire/ — Christian Solidarity International (CSI-USA) Chairman John Eibner issued the following statement following the ground-breaking June 22 The American Conservative exposé “How America Armed Terrorists in Syria” written by Gellhorn Prize award winning investigative journalist Gareth Porter:

Gareth Porter’s “How America Armed Terrorists in Syria” is a wake-up call that must be answered by the Trump administration and Congress. It is no longer possible to pretend that U.S. policy under the past administration was not directly involved in arming the most violent jihadi terror groups operating in Syria.  The al-Nusra Front – the official al-Qaeda affiliate in Syria – was among the jihadist beneficiaries of CIA programs to transfer weapon from Libya and the Balkans. These transfers took place with full knowledge of the violent nature of these groups, which among other outrages commit countless acts of murder, torture, plunder and forced conversions of Christians and other non-Sunni Muslims.  In my many travels to Syria since 2013, I have met with a host of innocent victims of their acts of terror. Arming al-Qaeda and its jihadist collaborators also led to the emergence of ISIS, originally an al-Qaeda offshoot, thus increasing the terror threat to Americans inside our own country.

“It should not require an act of Congress to stop our tax money going to arm al-Qaeda and its collaborators. The While House could stop this practice immediately, if it had the will. While Porter’s article concerns activities taking place before the current administration took office, there is no guarantee the U.S. is not continuing “business as usual” with their local clients and terror-funding partners like Saudi Arabia, Qatar, and Turkey. 

“In Riyadh last month, President Trump told representatives of more than 50 Muslim-majority countries that the funding and arming of terrorists must end. This sound initiative would gain hugely in force and credibility if the President would lead by example. He should give an unambiguous order to end this policy immediately. But there is growing concern that he will instead follow the example of his predecessor by ramping up covert support for al-Qaeda and other Sunni jihadists as boots on the ground against Shiite Iran and its regional interests.  

“Porter begins and ends his expose with reference to the “Stop Arming Terrorists Act” (SATA) introduced by Rep. Tulsi Gabbard and Sen. Rand Paul. This bill would prohibit any U.S. assistance to al-Qaeda and ISIS, and any organization working directly with them. It would also prohibit U.S. military sales to countries that provide arms or financing to terrorists. Christian Solidarity International fully supports the principles and purposes of this legislation and calls on the Trump administration to cut off U.S. arms to jihadi terrorists, totally and permanently with out further delay.”

In his The American Conservative investigate report, Porter writes: “Gabbard’s “Stop Arming Terrorists Act” challenges for the first time in Congress a U.S. policy toward the conflict in the Syrian civil war that should have set off alarm bells long ago: in 2012-13 the Obama administration helped its Sunni allies Turkey, Saudi Arabia, and Qatar provide arms to Syrian and non-Syrian armed groups to force President Bashar al-Assad out of power. And in 2013 the administration began to provide arms to what the CIA judged to be “relatively moderate” anti-Assad groups—meaning they incorporated various degrees of Islamic extremism.

“The supporters of this arms-supply policy believe it is necessary as pushback against Iranian influence in Syria. But that argument skirts the real issue raised by the policy’s history.  The Obama administration’s Syria policy effectively sold out the U.S. interest that was supposed to be the touchstone of the “Global War on Terrorism”—the eradication of al Qaeda and its terrorist affiliates. The United States has instead subordinated that U.S. interest in counter-terrorism to the interests of its Sunni allies. In doing so it has helped create a new terrorist threat in the heart of the Middle East.”

CSI is an international Christian human rights organization, campaigning for religious liberty and human dignity, and assisting victims of religious persecution, victimized children and victims of catastrophe, in accordance with the Universal Declaration of Human Rights. 

For more information on No Arms for Terrorists, please visit

For More Information Contact:
Darren Spinck, Global Strategic Communications Group
202-669-4418 or

John Eibner, Christian Solidarity International

SOURCE No Arms For Terrorists

Rivel Research Group Releases Largest Ever Global Investor Relations Compensation Study

Adding Board-level Engagement, Corporate Governance, Strategic Planning or M&A Advisory Activities Lead to Greatest Compensation Gains

SAN DIEGO, June 26, 2017 /PRNewswire/ — Rivel Research Group, a global leader in investor market research and analytics, today revealed the US portion of its latest corporate Investor Relations Officer (IRO) compensation data at its semi-annual conference held in San Diego. Extracted from a profile of 1703 global professionals, this study is unprecedented in its size and international reach.

Nearly three-quarters (72%) of the head US IROs reported a salary increase from Rivel’s study conducted in 2015. Other major findings from the study include:

  • 2016 median base salaries rose to $230,000 from $210,000 in 2014, an increase of almost 10%.
  • Stock grants and cash bonuses remained relatively flat compared with 2014.
  • More than 80% of head US IROs received all three components – base salary, stock grants and cash bonuses – of the compensation package.
  • 95% of head US IROs received a cash bonus. The median cash value was $70,000.
  • 87% of head US IROs received a stock grant. The media cash value of the stock grant was $110,000.

“This study, similar to our study conducted in 2015, highlights the path for IROs to higher compensation, providing them with the tools necessary to drive those higher compensation packages and also the understanding of what separates the highly compensated IROs from the rest of the pack,” said Brian Rivel, President of Rivel Research Group. “The head IRO responsibilities continue to grow through the years with higher compensation commensurate with those responsibilities. If an IRO adds another strategic element to his or her already immense responsibilities, the payoff could be quite substantial, resulting in as much as 29% gains in stock grants and/or cash bonuses.”

The size of the company and additional high-level responsibilities both matter greatly in the path to higher compensation:

  • The median base salary, bonus and stock grants of S&P 500 large-cap head IROs were all significantly higher compared with S&P 400 mid-cap and S&P 600 small-cap companies, as outlined in the table below:

S&P 500

S&P 400

S&P 600





Base salary








Stock grants




Rivel Research Group’s data shows that head IROs with additional responsibilities that include one or more of the following lead to the highest compensation levels:

  • Board-level engagement with attendance at board meetings,
  • Corporate governance activities,
  • High-level strategic planning
  • M&A advisory

Rivel Research Group has been conducting corporate IRO compensation studies since 1991. Rivel gathered data electronically on a global basis during the spring of 2017 for the IRO Compensation study. Rivel Research Group will be releasing its full findings, including international results, next month.

For more information on the study, please contact Sean McCurdy at or (203) 493-2333.

About Rivel Research Group
Since 1991, Rivel Research Group has been the global leader in perception studies, research and predictive analytics within the investment community. We help public companies maximize long-term valuation through best practices in investor relations and corporate governance. With more than 600 clients on six continents, our methodology of in-depth interviews, measurements and analysis provide our clients with meaningful and sentiment changing qualitative and quantitative intelligence. Additional information can be found at

SOURCE Rivel Research Group

MiniTool News: MiniTool Released the Best Backup Solution MiniTool ShadowMaker

VANCOUVER, British Columbia, June 26, 2017 /PRNewswire/ — MiniTool Solution Ltd. today announced the release of MiniTool ShadowMaker Beta 2.0 – a brand new yet professional data protection solution.

MiniTool ShadowMaker Beta 2.0 is an all-in-one disk partition backup and disaster recovery solution for PCs. What can it handle? No matter whether you need to back up Windows OS, selected partitions, and even the whole disk, you just turn to it. With a copy of backup, you are able to restore computer to a previous state once a disaster occurs, like system crash, hard drive failure, etc. It is FREE for home users now but does not support Windows Server. 

Main Features:

MiniTool ShadowMaker is capable of dealing with many backup tasks. As free backup software, this is indeed praiseworthy.

Benefits with this beta version:

  1. Local/Remote Backup: enables to back up the local computer or remote computer in the same LAN.
  2. Backup System: Back up Windows system in case that some day it fails to boot.
  3. Back up Disk: Back up basic disk, including the system disk to make the most intact copy of your data.
  4. Schedule Backup: Schedule backup task and set to back up daily weekly, monthly or on event.
  5. Manage Backup: Manage backup tasks such as to add differential and incremental backups based on the former backups, to restore a backup image.
  6. Universal Restore: Restore Windows operating system to a bare computer or dissimilar hardware. In this way, you successfully avoid tedious reinstall of OS and applications.
  7. Bootable Media Builder: Create WinPE-based bootable media to restore system to a normal state when there is a need.

Improvements on Old Functions:

Based on the original system backup function, this backup software has gained the following new features:

  1. Totally new interface, clear and intuitive.
  2. Separate Restore feature to the main interface.
  3. Automatically detect and add existed backup files to backup list in Windows and WinPE.
  4. Support inputting IP address and PC name to NAS path, and enhance the ability to check whether a NAS path is valid.
  5. Some bug fixes.

The beta version is totally free for Windows home users. Those who are interested in the beta testing can never miss out.


About MiniTool Solution Ltd.:

MiniTool Solution Ltd. is a software development company located in Canada. After years of development, now it has become a professional data care company, which offers multiple programs to help users resolve issues: its partition manager software – MiniTool Partition Wizard is effective in disk partition management; the data recovery software – MiniTool Power Data Recovery is devoted to recovering lost/deleted data due to various causes; and Mobile Recovery for iOS/Android are recent data recovery software solutions. Now MiniTool ShadowMaker is released to make up for the deficiency of disk imaging software.



This release was issued through Send2Press®, a unit of Neotrope®. For more information, visit Send2Press Newswire at


SOURCE MiniTool Solution Ltd.

Canon U.S.A. Congratulates EO Johnson on 60 Years of Business

MELVILLE, N.Y., June 26, 2017 /PRNewswire/ — In recognition of the importance of maintaining strong relationships with its dealers, Canon U.S.A., a leader in digital imaging solutions, would like to congratulate EO Johnson Business Technologies on their sixtieth anniversary. Based in the upper mid-west, EO Johnson has provided a variety of print and business technology services to their customers since its inception in 1957. Since 1979, EO Johnson has brought Canon’s imaging devices and solutions to their clients, which was a critical step in their growth as a company.

“It is with great pride that Canon congratulates our partner EO Johnson on this monumental occasion,” said Toyotsugu Kuwamura, executive vice president and general manager, Business Imaging Solutions Group, Canon U.S.A., Inc. “Canon greatly appreciates the valuable relationships it maintains with our dealers, especially with a company with a storied history like EO Johnson. For decades, EO Johnson and Canon have worked hand-in-hand to help provide customers with the tools that they need to continue to thrive in the fast-paced world of business. We look forward to this relationship continuing well into the future.”  

“My dad, Emery O. Johnson, dared to imagine in 1957 when he saw an innovative, new product and founded his business on selling and servicing copy machines,” said Mary Jo Johnson, CEO/Owner, EO Johnson Business Technologies.  “Sixty years later I know he would be proud of the vendor partnerships we have, the dedication each and every one of our employees has to our core values and customer service, and the truly amazing customer base we are blessed to have.”

Sixty years ago, EO Johnson was founded by Emery (E.O.) Johnson, who started the company by selling, serving and supporting copier devices throughout Wisconsin. Over the years, the company has expanded its footprint to include a variety of locations in six markets throughout Minnesota and Iowa, in addition to Wisconsin. The company now employs 280+ employees and includes seven different product divisions to meet a variety of customer demands. As a sign of its continuing support for their customers, EO Johnson plans to hold a series of market-specific open house events through the year.

For more information on Canon U.S.A., please visit

About EO Johnson Business Technologies 
EO Johnson Business Technologies is a leading business technologies provider, offering managed IT services, managed print services, document management, scanning and business processes systems, and print/document and production printing equipment.  EO Johnson is certified as a Woman Owned Business through the State of Wisconsin and a 2016 BBB Torch Award for Ethics winner.

About Canon U.S.A., Inc.
Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions to the United States and to Latin America and the Caribbean markets. With approximately $29 billion in global revenue, its parent company, Canon Inc. (NYSE: CAJ), ranks third overall in U.S. patents granted in 2016. Canon U.S.A. is committed to the highest level of customer satisfaction and loyalty, providing 100 percent U.S.-based consumer service and support for all of the products it distributes in the United States. Canon U.S.A. is dedicated to its Kyosei philosophy of social and environmental responsibility. In 2014, the Canon Americas Headquarters secured LEED® Gold certification, a recognition for the design, construction, operations and maintenance of high-performance green buildings. To keep apprised of the latest news from Canon U.S.A., sign up for the Company’s RSS news feed by visiting and follow us on Twitter @CanonUSA. For media inquiries, please contact

Based on weekly patent counts issued by United States Patent and Trademark Office.

Canon U.S.A. Web site: 

For sales information/customer support:

SOURCE Canon U.S.A., Inc.

Hundreds of Thousands of Veterans Have Opted for Patriotic Designation on Their Pennsylvania Driver’s License, ID Card

ANNVILLE, Pa., June 26, 2017 /PRNewswire-USNewswire/ — More than 440,000 veterans have had the veterans designation added to their Pennsylvania driver’s license or ID card since the option was made available in 2014. The designation – an American flag with the word Veteran beneath it – is a patriotic way for veterans to show their pride and convey to others that they served in the United States military.

“People flash their driver’s license or ID card more often than we think, which makes the veterans designation an ideal way for veterans to show others how proud they are to have served in the armed forces,” said Brig. Gen. Tony Carrelli, Pennsylvania’s adjutant general. “The American flag is a symbol of freedom and liberty throughout the world. Our veterans proudly display the red, white, and blue icon on their license signifying their dedicated service to this great nation.”

Qualified applicants for a veterans designation must have served in the United States Armed Forces and/or the reserve component, and have been discharged or released from service under conditions other than dishonorable.

“The number of veterans taking advantage of the designation is indicative of how honored they are to have protected this country and represented this commonwealth,” said PennDOT Secretary Leslie S. Richards. “We are equally honored to partner with the Department of Military and Veterans Affairs to bring this program to these worthy veterans.”

There is no fee for the veterans designation, however regular renewal or duplicate fees still apply. Forms for driver’s license or ID renewals and duplicates have a box for applicants to certify that they are a veteran, and to have the designation added. Once the veterans designation has been added to a driver’s license or identification card, it will automatically appear each time the card is renewed. 

Veterans holding a non-commercial driver’s license or identification card can immediately apply for the designation by visiting and clicking on the American flag/veterans designation icon.

To renew a commercial driver’s license (CDL) and add the veterans designation, applicants must complete and mail in a DL-143CD form and applicable fees. To obtain a duplicate CDL with the veterans designation, applicants must complete and mail in a DL-80CD form and applicable fees.

The veterans designation does not entitle a veteran to any special consideration or discount but rather identifies the bearer as a veteran. Any other recognition such as a discount, free meal or other token of appreciation is completely and solely determined by the organization, business or entity providing a service.

MEDIA CONTACT: Joseph Butera, 717-861-2178

SOURCE Pennsylvania Department of Military and Veterans Affairs; Pennsylvania Department of Transportation